<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37924472</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>Blood T cell phenotypes correlate with fatigue severity in post-acute sequelae of COVID-19.</ArticleTitle><Pagination><StartPage>513</StartPage><EndPage>524</EndPage><MedlinePgn>513-524</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-023-02114-8</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Post-acute sequelae of COVID-19 (PASC) affect approximately 10% of convalescent patients. The spectrum of symptoms is broad and heterogeneous with fatigue being the most often reported sequela. Easily accessible blood biomarkers to determine PASC severity are lacking. Thus, our study aimed to correlate immune phenotypes with PASC across the severity spectrum of COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 176 originally immunona&#xef;ve, convalescent COVID-19 patients from a prospective cohort during the first pandemic phase were stratified by initial disease severity and underwent clinical, psychosocial, and immune phenotyping around 10&#xa0;weeks after first COVID-19 symptoms. COVID-19-associated fatigue dynamics were assessed and related to clinical and immune phenotypes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fatigue and severe fatigue were commonly reported irrespective of initial COVID-19 severity or organ-specific PASC. A clinically relevant increase in fatigue severity after COVID-19 was detected in all groups. Neutralizing antibody titers were higher in patients with severe acute disease, but no association was found between antibody titers and PASC. While absolute peripheral blood immune cell counts in originally immunona&#xef;ve PASC patients did not differ from unexposed controls, peripheral CD3<sup>+</sup>CD4<sup>+</sup> T cell counts were independently correlated with fatigue severity across all strata in multivariable analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients were at similar risk of self-reported PASC irrespective of initial disease severity. The independent correlation between fatigue severity and blood T cell phenotypes indicates a possible role of CD4<sup>+</sup> T cells in the pathogenesis of post-COVID-19 fatigue, which might serve as a blood biomarker.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Pink</LastName><ForeName>Isabell</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. pink.isabell@mh-hannover.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany. pink.isabell@mh-hannover.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hennigs</LastName><ForeName>Jan K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, II. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruhl</LastName><ForeName>Louisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), TTU-IICH, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauer</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boblitz</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huwe</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, II. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuge</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falk</LastName><ForeName>Christine S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietschmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Experimental Virology, Hannover Medical School, TWINCORE Research Center, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Zwaan</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasse</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kluge</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klose</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, II. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoeper</LastName><ForeName>Marius M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welte</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>COFONI-2FF4</GrantID><Agency>COVID-19 -Research Network of the State of Lower Saxony (COFONI), Ministry of Science and Culture of Lower Saxony, Germany</Agency><Country/></Grant><Grant><GrantID>14-76103-184 CORONA-13/20</GrantID><Agency>COVID-19 -Research Network of the State of Lower Saxony (COFONI), Ministry of Science and Culture of Lower Saxony, Germany</Agency><Country/></Grant><Grant><GrantID>project 07_913</GrantID><Agency>Deutsches Zentrum f&#xfc;r Infektionsforschung</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="Y">T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fatigue assessment scale</Keyword><Keyword MajorTopicYN="N">Immune phenotypes</Keyword><Keyword MajorTopicYN="N">Immunodysregulation</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>IP has received fees for lectures from Boehringer Ingelheim and AstraZeneca outside the submitted work; JKH has received grants, contracts, and/or fees for lectures and/or consultations from Boehringer Ingelheim, Janssen, Pfizer, and Years outside the submitted work; JF reports personal fees/speaker honoraria from AstraZeneca outside the submitted work; AP reports speaker honoraria from Boehringer Ingelheim, Novartis, Gilead, Amgen outside the submitted work; MMH has received fees for lectures and/or consultations from Acceleron, AOP Health, Bayer, Ferrer, Janssen, and MSD outside the submitted work; TW has received fees for lectures and/or consultations from AstraZeneca, Berlin-Chemie, Boehringer, GSK, Insmed, Janssen, Moderna, Novartis, Pfizer, Roche, Sanofi Aventis, and Shionogi outside the submitted work; SK has received fees for lectures and/or consultations from Gilead, MSD, Shionogi, and Pfizer outside the submitted work; AP, LB, LR, CSF, MdZ, and TP have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>21</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>4</Day><Hour>21</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>4</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37924472</ArticleId><ArticleId IdType="pmc">PMC10954951</ArticleId><ArticleId IdType="doi">10.1007/s15010-023-02114-8</ArticleId><ArticleId IdType="pii">10.1007/s15010-023-02114-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC Weekly C, The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) &#x2014; China. China CDC Wkly 2:113&#x2013;122. 10.46234/ccdcw2020.032</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8392929</ArticleId><ArticleId IdType="pubmed">34594836</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, Klauber J, Janssens U, Marx G, Weber-Carstens S, Kluge S, Pfeifer M, Grabenhenrich L, Welte T, Busse R. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8:853&#x2013;862. doi: 10.1016/S2213-2600(20)30316-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30316-7</ArticleId><ArticleId IdType="pmc">PMC7386882</ArticleId><ArticleId IdType="pubmed">32735842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O&#x2019;Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021 doi: 10.1136/bmj.n1088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1088</ArticleId><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 2 Nov 2021</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021 doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, Molteni E, Modat M, Jorge Cardoso M, May A, Ganesh S, Davies R, Nguyen LH, Drew DA, Astley CM, Joshi AD, Merino J, Tsereteli N, Fall T, Gomez MF, Duncan EL, Menni C, Williams FMK, Franks PW, Chan AT, Wolf J, Ourselin S, Spector T, Steves CJ. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, Adamo S, Raeber ME, B&#xe4;chli E, Rudiger A, St&#xfc;ssi-Helbling M, Huber LC, Nilsson J, Held U, Puhan MA, Boyman O. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13:446. doi: 10.1038/s41467-021-27797-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennigs JK, Oqueka T, Harbaum L, Klose H. Organbezogene Folgeerscheinungen von COVID-19 bei Erwachsenen. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2022;65:462&#x2013;470. doi: 10.1007/s00103-022-03513-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00103-022-03513-2</ArticleId><ArticleId IdType="pmc">PMC8925979</ArticleId><ArticleId IdType="pubmed">35294563</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, Horn C, Vanshylla K, Cristanziano VD, Osebold L, Roventa M, Riaz T, Tschernoster N, Altmueller J, Rose L, Salomon S, Priesner V, Luers JC, Albus C, Rosenkranz S, Gathof B, F&#xe4;tkenheuer G, Hallek M, Klein F, Su&#xe1;rez I, Lehmann C. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health - Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, Juno JA, Burrell LM, Kent SJ, Dore GJ, Kelleher AD, Matthews GV. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Vries J, Michielsen H, Heck GL, Drent M. Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS) Br J Health Psychol. 2004;9:279&#x2013;291. doi: 10.1348/1359107041557048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1348/1359107041557048</ArticleId><ArticleId IdType="pubmed">15296678</ArticleId></ArticleIdList></Reference><Reference><Citation>de Kleijn WPE, De Vries J, Wijnen PAHM, Drent M. Minimal (clinically) important differences for the fatigue assessment scale in sarcoidosis. Respir Med. 2011;105:1388&#x2013;1395. doi: 10.1016/j.rmed.2011.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2011.05.004</ArticleId><ArticleId IdType="pubmed">21700440</ArticleId></ArticleIdList></Reference><Reference><Citation>Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40:255&#x2013;263. doi: 10.1183/09031936.00002512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00002512</ArticleId><ArticleId IdType="pubmed">22441750</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Boon GJAM, Barco S, Endres M, Geelhoed JJM, Knauss S, Rezek SA, Spruit MA, Vehreschild J, Siegerink B. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56:2001494. doi: 10.1183/13993003.01494-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01494-2020</ArticleId><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Band17_DemographischeStandards1030817169004.pdf</Citation></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, M&#xfc;ller MA, Drosten C, P&#xf6;hlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, Lynn MA, Mekonnen ZA, Yeow AEL, Garcia-Valtanen P, Al-Delfi Z, Gummow J, Ferguson C, O&#x2019;Connor S, Reddi BAJ, Hissaria P, Shaw D, Kok-Lim C, Gleadle JM, Beard MR, Barry SC, Grubor-Bauk B, Lynn DJ. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20:26. doi: 10.1186/s12916-021-02228-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhl L, Pink I, K&#xfc;hne JF, Beushausen K, Keil J, Christoph S, Sauer A, Boblitz L, Schmidt J, David S, J&#xe4;ck H-M, Roth E, Cornberg M, Schulz TF, Welte T, H&#xf6;per MM, Falk CS. Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks. Signal Transduct Target Ther. 2021;6:418. doi: 10.1038/s41392-021-00819-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00819-6</ArticleId><ArticleId IdType="pmc">PMC8661333</ArticleId><ArticleId IdType="pubmed">34893580</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A, Chappert P, Barba-Spaeth G, Roeser A, Fourati S, Azzaoui I, Vandenberghe A, Fernandez I, Meola A, Bouvier-Alias M, Crickx E, Beldi-Ferchiou A, Hue S, Languille L, Michel M, Baloul S, Noizat-Pirenne F, Luka M, M&#xe9;gret J, M&#xe9;nager M, Pawlotsky J-M, Fillatreau S, Rey FA, Weill J-C, Reynaud C-A, Mah&#xe9;vas M. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021;184:1201&#x2013;1213.e14. doi: 10.1016/j.cell.2021.01.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.050</ArticleId><ArticleId IdType="pmc">PMC7994111</ArticleId><ArticleId IdType="pubmed">33571429</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes CO, Bram Y, Breton G, H&#xe4;ggl&#xf6;f T, Mendoza P, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tankelevich M, Martinez-Delgado G, Yee J, Patel R, Dizon J, Unson-O&#x2019;Brien C, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Schwartz RE, Hatziioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig MC. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhl L, K&#xfc;hne JF, Beushausen K, Keil J, Christoph S, Sauer J, Falk CS. Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern. Front Immunol. 2023;14:1120010. doi: 10.3389/fimmu.2023.1120010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1120010</ArticleId><ArticleId IdType="pmc">PMC10073596</ArticleId><ArticleId IdType="pubmed">37033958</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X-R, Geng R, Li Q, Chen Y, Li S-F, Wang Q, Min J, Yang Y, Li B, Jiang R-D, Wang X, Zheng X-S, Zhu Y, Jia J-K, Yang X-L, Liu M-Q, Gong Q-C, Zhang Y-L, Guan Z-Q, Li H-L, Zheng Z-H, Shi Z-L, Zhang H-L, Peng K, Zhou P. ACE2-independent infection of T lymphocytes by SARS-CoV-2. Signal Transduct Target Ther. 2022;7:83. doi: 10.1038/s41392-022-00919-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00919-x</ArticleId><ArticleId IdType="pmc">PMC8914143</ArticleId><ArticleId IdType="pubmed">35277473</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23:186&#x2013;193. doi: 10.1038/s41590-021-01122-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Polat Ekinci A, B&#xfc;y&#xfc;kbabani N, Me&#x15f;e S, Pehlivan G, Okumu&#x15f; NG, A&#x11f;a&#xe7;fidan A, &#xd6;zkaya E. COVID-19-triggered sarcoidal granulomas mimicking scar sarcoidosis. J Eur Acad Dermatol Venereol. 2021 doi: 10.1111/jdv.17286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17286</ArticleId><ArticleId IdType="pmc">PMC8250646</ArticleId><ArticleId IdType="pubmed">33871106</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia-Ramos AE, Martin-Nares E, Hern&#xe1;ndez-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021;10:3592. doi: 10.3390/cells10123592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123592</ArticleId><ArticleId IdType="pmc">PMC8700122</ArticleId><ArticleId IdType="pubmed">34944099</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennigs JK, Huwe M, Hennigs A, Oqueka T, Simon M, Harbaum L, K&#xf6;rbelin J, Schmiedel S, Schulze Zur Wiesch J, Addo MM, Kluge S, Klose H. Respiratory muscle dysfunction in long-COVID patients. Infection. 2022;50:1391&#x2013;1397. doi: 10.1007/s15010-022-01840-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-022-01840-9</ArticleId><ArticleId IdType="pmc">PMC9108020</ArticleId><ArticleId IdType="pubmed">35570238</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>